The EPO’s plausibility approach and the industrial application requirement in biotech patenting
Activity: Talk or presentation types › Lecture and oral contribution
Timo Minssen - Lecturer
- Faculty of Law Research Centres
- Centre for Information and Innovation Law
The EPO’s plausibility approach and the industrial application requirement in biotech patenting
This presentation will discuss the most recent developments relating to the “industrial application” requirement with a special emphasis on gene and protein-related inventions in Europe. In addition to providing a brief overview of the applicable legislative framework, this presentation will address relevant EPO practice and the UK Supreme Court’s seminal decision in HGS v Eli Lilly.
A presentation given at a 5 days intensive training for practitioners/professionals in Pharma Law & Policy (CSU), 13 – 17 August 2012, 9, at the University of Copenhagen, Frederiksberg Campus
This presentation will discuss the most recent developments relating to the “industrial application” requirement with a special emphasis on gene and protein-related inventions in Europe. In addition to providing a brief overview of the applicable legislative framework, this presentation will address relevant EPO practice and the UK Supreme Court’s seminal decision in HGS v Eli Lilly.
A presentation given at a 5 days intensive training for practitioners/professionals in Pharma Law & Policy (CSU), 13 – 17 August 2012, 9, at the University of Copenhagen, Frederiksberg Campus
13 Aug 2012
Event (Course)
Title | Pharmaceutical Law & Policy- Hot topics shaping the future of the pharma industry |
---|---|
Abbreviated title | CSU |
Date | 13/08/2012 → 17/08/2012 |
Location | University of Copenhagen, Frederiksberg Campus |
City | Copenhagen |
Country/Territory | Denmark |
ID: 40312533